Roche pays $510 million for rights to Chinese cancer-drug portfolio

Roche is committing $510 million upfront to secure rights to a new group of Chinese-developed cancer-drug candidates. The Basel-based pharmaceutical company has struck a deal with Hansoh Pharma for a portfolio of antibody-drug conjugates, or ADCs, a class of medicines designed to deliver chemotherapy to tumours using an antibody as a targeting component.

The agreement gives Hansoh responsibility for early development, through completion of the first clinical phase. Roche then takes over global development, with mainland China, Hong Kong, Macao and Taiwan carved out of its territory. That division gives the companies distinct roles: Hansoh advances the candidates through the initial clinical stage, while Roche assumes responsibility for development across most international markets after that point.

The deal’s value combines immediate payments with potential future obligations. Roche will pay $400 million when the contract is signed and another $110 million a year later. Hansoh’s announcement also provides for $15 billion in milestone-linked payments tied to development, regulatory or commercial progress, as well as commissions on revenue. The agreement deepens a relationship between the two drugmakers that began with a separate transaction last year.

Hansoh will lead the candidates through their first clinical phase before Roche assumes global development responsibility. The handover is central to the agreement: the Shanghai-based company will manage early work, while Roche takes over after that initial clinical stage, except in mainland China, Hong Kong, Macao and Taiwan.

The regional carve-out means the arrangement is not a single worldwide transfer of rights. Hansoh retains the named territories, while Roche’s remit covers the rest of the globe under the terms described in the deal. The companies have not described the portfolio’s individual candidates in the supplied announcement, so the agreement’s immediate significance lies in the rights and development framework rather than a named medicine or a promised launch date.

ADCs combine an antibody with a chemotherapy molecule. The antibody is intended to help direct the drug toward tumour cells, bringing together targeted recognition and a cancer-killing payload. Each candidate still has to progress through clinical development and the relevant regulatory steps before it can reach patients. The agreement allocates those development responsibilities by stage, with Hansoh taking the early work and Roche leading internationally after the first clinical phase.

The contract sets out $510 million in upfront payments, followed by milestone-linked sums and revenue commissions. Roche is due to pay $400 million upon signing, then $110 million one year later. Those two instalments make up the stated upfront value of the transaction, which Keystone-SDA reports as CHF 420 million.

Hansoh’s announcement also provides for $15 billion in payments tied to development, regulatory or commercial milestones. The deal includes commissions on revenue as well. The milestone structure links further payments to progress and commercial outcomes, while the initial instalments provide the agreed payment schedule at the start of the partnership.

The headline figure for the upfront portion should be read separately from the milestone terms. The $510 million is the stated initial consideration, with the later milestone payments and revenue commissions set out as additional elements of the contract. That structure places the early development work with Hansoh and gives Roche rights to lead development globally after the first clinical phase, subject to the regional exceptions. The transaction therefore combines a defined initial payment timetable with payments connected to how the programme advances.

This is Roche’s second rights deal with Hansoh in a year. The companies first entered into an agreement exactly one year before the new transaction, when Roche acquired rights to Hansoh’s drug candidate HS-20110 for an initial payment of $80 million. At that time, HS-20110 was being studied in Phase I clinical trials in China and the United States for colorectal cancer and other cancers.

The new agreement expands the commercial relationship from one named candidate to a portfolio of ADCs. The earlier deal concerned HS-20110, while the latest transaction covers rights to a broader group of antibody-drug conjugates. The arrangements have different reported upfront values and should not be conflated: $80 million was the initial payment for HS-20110, while $510 million is the upfront value attached to the new portfolio agreement.

For Roche, the transaction adds another collaboration with a Chinese pharmaceutical company to its cancer-drug development activity. Hansoh retains the early phase and the specified Asian territories, while Roche is positioned to lead global development elsewhere after the first clinical phase. The next concrete markers for the portfolio are its progress through that early clinical stage and the subsequent handover described in the agreement.